Biogen to Present 76-Week EMPAVELI Kidney Data at ASN
The data will show sustained proteinuria reduction and eGFR stabilization in C3G and primary IC-MPGN. Biogen will also share investigational felzartamab updates across kidney diseases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.